Clinical characteristics.

Carnitine palmitoyltransferase II (CPT II) deficiency is a disorder of long-chain fatty-acid oxidation. The three clinical presentations are lethal neonatal form, severe infantile hepatocardiomuscular form, and myopathic form (which is usually mild and can manifest from infancy to adulthood). While the former two are severe multisystemic diseases characterized by liver failure with hypoketotic hypoglycemia, cardiomyopathy, seizures, and early death, the latter is characterized by exercise-induced muscle pain and weakness, sometimes associated with myoglobinuria. The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and the most frequent cause of hereditary myoglobinuria. Males are more likely to be affected than females.

Diagnosis/testing.

The diagnosis of CPT II deficiency is established in a proband by the finding of reduced CPT enzyme activity in muscle or the identification of biallelic pathogenic variants in CPT2 on molecular genetic testing.

Management.

Treatment of manifestations: High-carbohydrate (70%) and low-fat (<20%) diet to provide fuel for glycolysis; use of carnitine to convert potentially toxic long-chain acyl-CoAs to acylcarnitines; avoidance of known triggers.

Prevention of primary manifestations: Infusions of glucose during intercurrent infections to prevent catabolism; frequent meals; avoiding extended fasting and prolonged exercise.

Prevention of secondary complications: Providing adequate hydration during an attack of rhabdomyolysis and myoglobinuria to prevent renal failure.

Agents/circumstances to avoid: Valproic acid, general anesthesia, ibuprofen, and diazepam in high doses.

Evaluation of relatives at risk: If the pathogenic variants have been identified in an affected family member, molecular genetic testing of at-risk relatives can reduce morbidity and mortality through early diagnosis and treatment; if the pathogenic variants in the family are not known, screening for alterations in acylcarnitines may be of use in identifying other affected family members.

Genetic counseling.

CPT II deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are usually asymptomatic; however, manifesting carriers have been reported. Prenatal testing for a pregnancy at increased risk for one of the severe forms of the disease is possible either by molecular genetic testing of CPT2, if the two pathogenic variants in the family are known, or by assay of CPT II enzyme activity.

Suggestive Findings

Carnitine palmitoyltransferase II (CPT II) deficiency should be suspected in individuals with the following clinical features (by age) and supportive laboratory findings.

Clinical features (by age)

• Lethal neonatal form presents within days after birth. Characterized by:
  • Episodes of liver failure with hypoketotic hypoglycemia
  • Cardiomyopathy
  • Cardiac arrhythmias
  • Seizures and coma after fasting or infection
  • Facial abnormalities or structural malformations (e.g., cystic renal dysplasia, neuronal migration defects or brain dysgenisis)
• Severe infantile hepatocardiomuscular form presents in the first year of life. Characterized by:
  • Liver failure
  • Cardiomyopathy
  • Seizures
  • Hypoketotic hypoglycemia
  • Peripheral myopathy
  • Attacks of abdominal pain and headache
• Myopathic form has variable onset (1st to 6th decade). Characterized by:
  • Recurrent attacks of myalgia accompanied by myoglobinuria precipitated by prolonged exercise (especially after fasting), cold exposure, or stress
  • Possible weakness during attacks
  • Usually no signs of myopathy (weakness, myalgia, elevation of serum creatine kinase [CK] concentration) between attacks

Supportive laboratory findings

• High-performance liquid chromatography tandem mass spectrometry of serum/plasma acylcarnitines (i.e, the acylcarnitine profile) that demonstrates an elevation of C12 to C18 acylcarnitines, notably of C16 and C18:1 (See Differential Diagnosis for other disorders with this acylcarnitine profile.)
  Note: CPT II deficiency cannot be excluded based on acylcarnitine quantification in dried blood spots alone and investigation of plasma is recommended [de Sain-van der Velden et al 2013].
• Serum CK concentration more than fivefold of normal when heart or brain disease is excluded
  • Most individuals with the myopathic form of CPT II deficiency have normal serum CK concentration (<80 U/L) between attacks.
  • Permanent elevation of serum CK concentration (≤313 U/L) is observed in approximately 10% of affected individuals [Wieser et al 2003].

Establishing the Diagnosis

The diagnosis of CPT II deficiency is established in a proband by the finding of reduced CPT enzyme activity in muscle or by the identification of biallelic pathogenic (or likely pathogenic) variants in CPT2 on molecular genetic testing (see Table 1).

Note: Per ACMG variant interpretation guidelines, the terms "pathogenic variants" and "likely pathogenic variants" are synonymous in a clinical setting, meaning that both are considered diagnostic and both can be used for clinical decision making. Reference to "pathogenic variants" in this section is understood to include any likely pathogenic variants.

Molecular genetic testing approaches can include single-gene testing and use of a multigene panel:

• Single-gene testing. Sequence analysis of CPT2 is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.
• A multigene panel that includes CPT2 and other genes of interest (see Differential Diagnosis) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this GeneReview; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition while limiting identification of variants of uncertain significance and pathogenic variants in genes that do not explain the underlying phenotype. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing-based tests.
  For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic tests can be found here.

Clinical Description

Three carnitine palmitoyltransferase II (CPT II) deficiency phenotypes are recognized: a lethal neonatal form; a severe infantile hepatocardiomuscular form; and a myopathic form, in which onset ranges from infancy to adulthood.

Genotype-Phenotype Correlations

A consistent genotype-phenotype correlation is found between CPT2 missense pathogenic variants (including the common p.Ser113Leu) and the myopathic form; these are referred to as pathogenic variants that cause "mild" form of the disease. CPT2 pathogenic null variants leading either to truncation of the protein or to mRNA degradation are referred to as pathogenic variants associated with the lethal neonatal form. However, several pathogenic variants are associated with both the mild and severe forms of CPT II deficiency, suggesting a role for other unknown modulators (intragenic variants; epigenetic or environmental factors) [Vladutiu et al 2000b, Musumeci et al 2007]. For a list of variants and their predicted phenotype, see Isackson et al [2008], Anichini et al [2011], and Fanin et al [2012].

Lethal neonatal form. Homozygosity for the severe pathogenic variants p.Pro227Leu, p.Lys414ThrfsTer7, and p.Lys642ThrfsTer6 [Isackson et al 2008] is associated with the lethal neonatal form. This subtype of the disease is also described in compound heterozygous states in combination with a pathogenic variant usually associated with mild disease (c.[1737delC];[520G>A]) [Semba et al 2008].

Severe infantile hepatocardiomuscular form. Compound heterozygosity for pathogenic variants associated with mild and severe forms has been reported. A detailed analysis associated the following pathogenic variants with this type of the disease: p.Tyr120Cys, p.Arg151Gln, p.Asp328Gly, p.Arg382Lys, p.Arg503Cys, p.Tyr628Ser, and p.Arg631Cys [Vladutiu et al 2002b, Thuillier et al 2003, Isackson et al 2008, Fanin et al 2012].

Myopathic form. The variant p.Ser113Leu accounts for 60% of pathogenic alleles in the myopathic form of CPT II deficiency. In a series of 32 affected individuals, 14 were homozygous for this common allele [Wieser et al 2003]; 17 were compound heterozygous for this common pathogenic variant and a second pathogenic variant. Testing for the p.Ser113Leu variant alone would suggest the diagnosis in 31 out of 32 individuals.

In northern Europeans the pathogenic variants p.Ser113Leu, p.Pro50His, and p.Lys414ThrfsTer7 are most frequently found, whereas in the Japanese the variant p.Phe383Tyr appears to have the highest prevalence [Taggart et al 1999, Isackson et al 2008, Yasuno et al 2008].

Heterozygotes have a biochemically intermediate phenotype (with markedly reduced enzyme activity) but generally do not display symptoms. However, a few symptomatic heterozygotes have been reported [Taggart et al 1999, Olpin et al 2003, Rafay et al 2005, Fanin et al 2012]. Heterozygotes have also been shown to have impaired fat oxidation during exercise as compared to controls [Ørngreen et al 2005].

Histopathologic changes in asymptomatic carriers of CPT II deficiency (heterozygotes) and in affected individuals (homozygotes) are inconsistent. A recent study found histopathologic abnormalities quite frequently (in all but one heterozygote). Lipid accumulation, found in all homozygotes, was mild or absent in heterozygotes.

Prevalence

Some twenty families with the lethal neonatal form [Smeets et al 2003, Thuillier et al 2003, Isackson et al 2008, Semba et al 2008, Boemer et al 2016] have been described. Since pregnancies in which a fetus has severe cerebral malformations are frequently interrupted, CPT II deficiency or other fatty acid oxidation disorders may be missed and the prevalence higher than previously suspected.

Approximately 28 families with the severe infantile hepatocardiomuscular form have been described.

Since the first description of the myopathic form of CPT II deficiency by DiMauro & DiMauro [1973], findings in more than 300 cases have been published [Thuillier et al 2003, Bonnefont et al 2004, Isackson et al 2006, Fanin et al 2012, Joshi et al 2013]. Symptoms of the myopathic form can be mild and physical impairment may not occur; thus, this form of CPT II deficiency may be under-recognized.

Neonatal Form

Carnitine-acylcarnitine translocase (CACT) deficiency. The neonatal phenotype of CACT deficiency, one of the most severe and usually lethal mitochondrial fatty-acid oxidation abnormalities, is characterized by hypoketotic hypoglycemia, hyperammonemia, cardiac abnormalities, and early death. Tandem mass spectrometry shows increased concentration of 16-2 H3 palmitoylcarnitine, suggesting either CPT II deficiency or CACT deficiency. One report shows that heat-denaturing high-performance liquid chromatography (DHPLC) is of use for diagnosing CACT deficiency [Fukushima et al 2013]. CACT deficiency is an autosomal recessive condition caused by compound heterozygous or homozygous pathogenic variants in SLC25A20.

Note: The differentiation of CACT deficiency from CPT II deficiency continues to be difficult using current acylcarnitine profiling techniques either from plasma or blood spots, or in the intact cell system (fibroblasts/amniocytes). Specific enzyme assays are required to unequivocally differentiate CACT enzyme activity from CPT II enzyme activity [Roe et al 2006].

Alternatively, molecular genetic testing could be used to distinguish between these two conditions.

Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a disorder of long-chain fatty-acid oxidation in which clinical symptoms usually occur with a concurrent febrile or gastrointestinal illness when energy demands are increased. The recognized phenotypes are: acute fatty liver of pregnancy, in which the fetus has biallelic pathogenic variants in CPT1A that cause CPT1A deficiency; and hepatic encephalopathy, in which individuals (typically children) present with hypoketotic hypoglycemia and sudden onset of liver failure. Individuals with hepatic encephalopathy typically present with hypoglycemia, absent or low levels of ketones, and elevated serum concentrations of liver transaminases, ammonia, and total carnitine.

The ratio of free-to-total carnitine in serum or plasma on a newborn screen bloodspot may be elevated in CPT1A deficiency. CPT1 enzyme activity on cultured skin fibroblasts is 1%-5% of normal in most affected individuals. In individuals with an enzymatically confirmed diagnosis of CPT1A deficiency, the CPT1A pathogenic variant detection frequency using sequence analysis is greater than 90%. Inheritance is autosomal recessive.

Myopathic Form

The myopathic form of CPT II deficiency is the most common disorder of lipid metabolism affecting skeletal muscle and is the most frequent cause of hereditary myoglobinuria. If clinical history is suggestive of a metabolic myopathy, routine laboratory tests including measurement of concentrations of lactate, pyruvate, creatine kinase, amino acids, and free acylcarnitine in blood should be performed. Careful family history should be taken. In early reports, elevation of acylcarnitines, notably C16 and C18:1, suggestive of a defect in mitochondrial β-oxidation, was detected by screening for acylcarnitines [Chace 2001]. Differential diagnosis of this finding includes CPT II deficiency, glutaric acidemia II (see Multiple Acyl-CoA Dehydrogenase Deficiency), carnitine-acylcarnitine translocase deficiency, and TANGO2-related metabolic encephalopathy and arrhythmias (a condition characterized by metabolic encephalomyopathic crises, rhabdomyolysis, cardiac arrhythmias, and neurodegeneration and caused by pathogenic variants in TANGO2). Unlike CPT II deficiency, TANGO2-related metabolic encephalopathy and arrhythmias is frequently accompanied by cardiac arrhythmias, cognitive impairment, epilepsy, spasticity, and brain atrophy. Additional tests are necessary to reach a definite diagnosis [Albers et al 2001].

Rhabdomyolysis and/or myoglobinuria. Rhabdomyolysis is etiologically heterogeneous, most cases being apparently acquired – for example, as a result of mechanical or vascular damage. Recurrent rhabdomyolysis preceded by exercise or infection is more likely to have an underlying metabolic defect, and strategic diagnostic procedures are warranted. History and physical examination are likely to identify the acquired and drug-related forms. However, one has to bear in mind that sometimes myoglobinuria with episodes of dark urine is ignored, and pronounced muscle pain after only light exercise is not considered a sign of disease. Screening for metabolic disorders (carnitine profile, amino acids, tandem mass spectrometry) may point in specific directions. Muscle biopsy for histologic and biochemical analysis should be performed. However, in a significant proportion of individuals, no cause of rhabdomyolysis can be identified.

Acquired causes of rhabdomyolysis

• Excessive use of muscle force (e.g., sports, seizures, dystonia)
• Muscle damage (e.g., crush, cold, ischemia, embolism)
• Infections (bacterial/viral/fungal)
• Temperature changes
• Inflammatory myopathies (polymyositis, vasculitis)

Drug-related causes of rhabdomyolysis

• Induction of an autoimmune reaction (e.g., cyclosporine, penicillamine)
• Hypokalemia (amphotericin, caffeine)
• Membrane disruption (cemitidin, colchicine)
• Disturbance of Na/K ATPase (antidepressants, arsen, azathioprine, bezafibrates)
• Neuroleptic syndrome (all neuroleptics, lithium)
• Serotonergic syndrome (amphetamines, MAO-inhibitor, SSRI)

Metabolic-toxic causes of rhabdomyolysis

• Defects of glucose/glycogen metabolism (e.g., McArdle disease, Tarui disease [OMIM 232800]). Deficiencies of the six enzymes involved in glycogen breakdown (phosphorylase, phosphorylase kinase, phosphofructokinase, phosphoglycerate kinase, phosphoglycerate mutase, lactate dehydrogenase) result in exercise intolerance and recurrent rhabdomyolysis.
• Defects of lipid metabolism (carnitine deficiency). Mitochondrial β-oxidation of long-chain fatty acids is a major source of energy production, particularly at times of stress or fasting. Skeletal muscle can use carbohydrates or lipids as fuel, depending on the degree of activity. At rest or during prolonged low-intensity exercise, approximately 70% of the energy requirement is met by the oxidation of long-chain fatty acids. Two defects of lipid metabolism primarily affecting the skeletal muscle are known: carnitine palmitoyltransferase II deficiency and systemic primary carnitine deficiency characterized by progressive proximal weakness and cardiomyopathy.
• Defects of oxidative phosphorylation (complex II deficiency, complex III defect, cytochrome c oxidase deficiency) (See Mitochondrial Disorders Overview.)
• TANGO2-related encephalopathy and arrhythmias
• Malignant hyperthermia (See Malignant Hyperthermia Susceptibility.)
• Dystrophinopathies (Duchenne muscular dystrophy, Becker muscular dystrophy)
• Myoadenylate deaminase deficiency (MAD) (OMIM 615511)

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with carnitine palmitoyltransferase II (CPT II) deficiency, the following are recommended:

• Neurologic examination
• Strength testing
• Review of dietary association of symptoms
• Consultation with a clinical geneticist and/or genetic counselor

Treatment of Manifestations

Current treatment for long-chain fatty-acid oxidation disorders:

• Avoid known triggers.
• Reduce the amount of long-chain dietary fat while covering the need for essential fatty acids.
• Provide carnitine to convert potentially toxic long-chain acyl-CoAs to acylcarnitines.
• Provide a large fraction of calories as carbohydrates to reduce body fat utilization and prevent hypoglycemia.
• Provide approximately one third of the calories as even-chain medium chain triglycerides (MCT). Metabolism of the eight to ten carbon fatty acids in MCT oil, for example, is independent of CPT I, carnitine-acylcarnitine translocase, CPT II, very long-chain acyl-CoA dehydrogenase (VLCAD), trifunctional protein, and long-chain hydroxy-acyl-CoA dehydrogenase deficiency (LCHAD) enzyme activities.

Prevention of Primary Manifestations

Appropriate measures include the following:

• Infusions of glucose during intercurrent infections to prevent catabolism
  Note: Oral glucose cannot achieve this effect.
• High-carbohydrate (70%) and low-fat (<20%) diet to provide fuel for glycolysis
• Frequent meals and avoidance of extended fasting
• Avoidance of prolonged exercise and other known triggers

Prevention of Secondary Complications

The most important aim while treating an individual with CPT II deficiency is to prevent renal failure during an episode of rhabdomyolysis and myoglobinuria. Therefore, sufficient hydration and, if necessary, dialysis must be performed immediately when renal failure is imminent.

Surveillance

Annual or more frequent monitoring to regulate medication and diet is indicated.

Agents/Circumstances to Avoid

Extended fasting and prolonged exercise are to be avoided.

Reports of medication-induced side effects in individuals with CPT II deficiency are rare. Relying mostly on case reports, the following agents should be avoided:

• Valproic acid [Kottlors et al 2001]
• General anesthesia
• Ibuprofen
• Diazepam in high doses [Bonnefont et al 1999]

Evaluation of Relatives at Risk

It is appropriate to evaluate apparently asymptomatic at-risk relatives so that morbidity and mortality can be reduced by early diagnosis and treatment. In addition, predictive testing for at-risk asymptomatic family members may be advisable before general anesthesia. Complications of general anesthesia (including rhabdomyolysis and suxamethonium hypersensitivity in individuals with a variety of neuromuscular diseases and renal post-anesthetic failure in individuals with CPT II deficiency in particular) have been observed [Katsuya et al 1988, Wieser et al 2008].

• Molecular genetic testing is appropriate if the pathogenic variants in the family are known.
• If the pathogenic variants in the family are not known, screening for alterations in acylcarnitines may be of use to identify other affected family members.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

While a variety of maternal complications have been observed in association with other fatty acid oxidation disorders (severe preeclampsia; acute fatty liver of pregnancy; maternal liver disease; and hemolysis, elevated liver enzymes, and low platelets), none of these complications has been associated with CPT II deficiency [Preece & Green 2002, Shekhawat et al 2005].

Therapies Under Investigation

Promising results have been obtained with treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using anaplerotic odd-chain triglycerides [Roe et al 2002]. These results were confirmed in seven individuals with CPT II deficiency, who avoided rhabdomyolysis or hospitalization while on the triheptanoin (anaplerotic) diet. Affected individuals returned to normal physical activity including strenuous sports [Roe et al 2008].

Fibrates are a class of hypolipidemic drugs that increase high-density lipoprotein levels by mRNA upregulation of many lipid-metabolism genes through interaction with the steroid/thyroid transcription factor PPARa. Studies have demonstrated that bezafibrate increases CPT2 mRNA and normalizes enzyme activity in mild forms of CPT II-deficient cultured fibroblasts and myoblasts [Bonnefont et al 2009]. In a trial including six affected individuals treated with bezafibrate, the level of fatty acid oxidation in muscle biopsies was elevated, accompanied by a significant increase in palmitoyl-L-carnitine oxidation, increased CPT2 mRNA, and increased translated protein. A reduction of episodes of rhabdomyolysis could be observed, as well as amelioration of quality of life (measured by SF-36) as shown by an increase in physical activity and a decline in muscular pain [Bonnefont et al 2009, Bonnefont et al 2010]. Another study did not show beneficial effects of bezafibrate on fatty acid oxidation and other disease manifestations; this study, however, was heavily criticized for methodologic shortcomings [Ørngreen et al 2014, Bastin et al 2015]

Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions.

Other

Carnitine supplementation is essentially a cure for the carnitine membrane transporter defect. While oral carnitine supplementation of 50 mg/kg/d is often prescribed in the treatment of other fat oxidation disorders, controlled trials of its effectiveness in CPT II deficiency are lacking. In addition, carnitine administration is controversial, given the possibility of accumulation of acyl-CoAs and consequent depletion of free CoA in the mitochondria [Yoshino et al 2003]. In acutely ill infants aggressive treatment with IV glucose and cardiac support is critical, and should be complemented with L-carnitine supplementation.

Mode of Inheritance

Carnitine palmitoyltransferase II (CPT II) deficiency is inherited in an autosomal recessive manner.

Risk to Family Members

Parents of a proband

• The parents of an affected individual are obligate heterozygotes (i.e., carriers of one CPT2 pathogenic variant).
• Heterozygotes (carriers) are generally asymptomatic; however, manifesting carriers for the p.Arg503Cys pathogenic variant have been reported [Vladutiu et al 2000a, Vladutiu 2001].
  Anichini et al [2011] identified only one pathogenic variant in 5/18 individuals with CPT II deficiency. While failure to detect the second pathogenic variant is the likely explanation, these individuals may instead represent symptomatic heterozygotes.

Sibs of a proband

• At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.
• Heterozygotes (carriers) are generally asymptomatic.

Offspring of a proband. The offspring of an individual with CPT II are obligate heterozygotes (carriers) for a pathogenic variant in CPT2.

Other family members. Each sib of the proband's parents is at a 50% risk of being a carrier of a CPT2 pathogenic variant.

Carrier (Heterozygote) Detection

Molecular genetic testing. Carrier testing should rely on molecular genetic methods if both CPT2 pathogenic variants have been identified in an affected family member.

Biochemical testing

• No data regarding the use of MS/MS for carrier detection are available.
• Carriers can be detected by measuring enzyme activity in muscle homogenates. Two unaffected carriers (parents), each carrying the common CPT2 p.Ser113Leu pathogenic variant (see Molecular Genetics), had normal total CPT II enzyme activity on routine testing, but intermediate activities of 30% and 44% after addition of malonyl-CoA and triton X, respectively [Wieser et al 2003].

Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

Family planning

• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal/preimplantation genetic testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.

DNA banking. Because it is likely that testing methodology and our understanding of genes, pathogenic mechanisms, and diseases will improve in the future, consideration should be given to banking DNA from probands in whom a molecular diagnosis has not been confirmed (i.e., the causative pathogenic mechanism is unknown).

Prenatal Testing and Preimplantation Genetic Testing

Molecular genetic testing. Once the CPT2 pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for CPT II deficiency are possible. Intrafamilial phenotypic homogeneity is a common feature in the lethal neonatal form and the severe infantile hepatocardiomuscular form of CPT II deficiency; however, data on prediction of the phenotype from prenatal test results are sparse and genotype-phenotype correlations remain inexact [Thuillier et al 2003, Joshi et al 2014].

Biochemical testing. Prenatal diagnosis for pregnancies at 25% risk is possible by analysis of enzyme activity of CPT II in cultured amniocytes and in freshly sampled chorionic villi [Vekemans et al 2003]. Deficient CPT II enzyme activity should be confirmed in an affected family member (usually an affected sib) before prenatal testing can be performed using enzyme assay. Tandem mass spectrometry analysis of the acylcarinitine profile in amniotic fluid supernatant has been attempted. Results from one affected fetus were normal, possibly due to the low excretion and poor solubility of long chain acylcarnitines in fetal urine. Therefore, prenatal diagnosis of CPT II deficiency cannot be reliably achieved through acylcarnitine analysis of amniotic fluid [Boemer et al 2016].

Ultrasound examination. Brain and/or renal abnormalities on fetal ultrasonography in the midtrimester of pregnancy have been identified in fetuses subsequently diagnosed to have CPT II deficiency using biochemical or molecular genetic testing [Elpeleg et al 2001, Sharma et al 2003].

Differences in perspective may exist among medical professionals if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.

Molecular Pathogenesis

The carnitine palmitoyltransferase enzyme system (CPT), in conjunction with acyl-CoA synthetase and carnitine-acylcarnitine translocase, mediates the entry of long-chain fatty acids (LCFA) into the mitochondrial matrix for β-oxidation. CPT II, encoded by CPT2, is located on the inner mitochondrial membrane. CPT I, another component of this system, is located on the outer membrane; one isoform of CPT I is associated with carnitine palmitoyltransferase 1A deficiency.

Gene structure. CPT2 spans 20 kb and contains five exons. For a detailed summary of gene and protein information, see Table A, Gene.

Benign variants (see Table 2). In persons of northern European heritage, two normal variants, p.Val368Ile and p.Met647Val, occur with a frequency of 0.5 and 0.25 respectively, exhibiting Hardy-Weinberg equilibrium. A third normal variant, p.Phe352Cys, occurs in the Japanese population [Wataya et al 1998].

Pathogenic variants (see Table 2). More than 90 CPT2 pathogenic variants have been identified, the majority are predicted to produce amino acid substitutions or small deletions [Isackson et al 2006, Isackson et al 2008, Anichini et al 2011, Fanin et al 2012, Joshi et al 2013].

• A so-called "common" variant, p.Ser113Leu, is present in exon 3 of CPT2. This variant is identified in approximately 60% of all mutated alleles.
• p.Lys414ThrfsTer7 was found in subsequent studies in eight affected individuals and is therefore the second-most common variant [Taggart et al 1999].
• Interestingly, the p.Phe448Leu amino acid substitution alone has no functional consequence [Deschauer et al 2005]. However, it is always found on the same allele (in cis) with the p.Lys414ThrfsTer7 frameshift variant, which is pathogenic because it predicts a premature termination codon. The mode of action of this complex mutated haplotype p.[Lys414ThrfsTer7;Phe448Leu] remains unclear.

Normal gene product. CPT II has a molecular weight of 60-70 kd. The initial translation product contains 658 amino acids.

Abnormal gene product. It has been proposed that the pathologic findings likely result from altered regulatory properties of the enzyme system rather than from a lack of catalytic activity, since enzyme activity is normal in affected individuals as well as in controls under optimal assay conditions, but the enzyme is abnormally inhibited by malonyl-CoA, an intrinsic inhibitor of this system.

The crystal structure of rat carnitine palmitoyltransferase II has led to new insights into possible pathologic mechanisms. It was shown that the overall structure shows similarity to other carnitine acyltransferases with structural differences in the active sites, which may have an effect on substrate selectivity. Regarding the most frequently mutated residue, serine-113, Hsiao et al [2006] report: "The side chain hydroxyl of Ser113 has a long hydrogen-bond with the gaunidinium group of Arg498, which in turn is ion-paired to Asp376, located four residues from the catalytic His372 residue. Therefore, the p.Ser113Leu variant may disturb this hydrogen-bonding and ion-pair network, and thereby indirectly affect the catalytic efficiency of the His372 residue."

Hsiao et al [2006] suggest that the p.Pro50His variant, which is 23 amino acids from the active site, results in an altered association of the enzyme with the mitochondrial membrane, thus impairing the transport of acylcarnitine substrate to the active site of CPT II.

Revision History

• 3 January 2019 (aa) Revision: TANGO2-related metabolic encephalopathy and arrhythmias added to Differential Diagnosis
• 16 March 2017 (ma) Comprehensive update posted live
• 15 May 2014 (me) Comprehensive update posted live
• 6 October 2011 (me) Comprehensive update posted live
• 25 June 2009 (me) Comprehensive update posted live
• 30 November 2006 (me) Comprehensive update posted live
• 27 August 2004 (me) Review posted live
• 7 October 2003 (tw) Original submission

Literature Cited

• Albers S, Marsden D, Quackenbush E, Stark AR, Levy HL, Irons M. Detection of neonatal carnitine palmitoyltransferase II deficiency by expanded newborn screening with tandem mass spectrometry. Pediatrics. 2001;107:E103. [PubMed: 11389301]
• Anichini A, Fanin M, Vianey-Saban C, Cassandrini D, Fiorillo C, Bruno C, Angelini C. Genotype-phenotype correlations in a large series of patients with muscle type CPT II deficiency. Neurol Res. 2011;33:24–32. [PubMed: 20810031]
• Bastin J, Bonnefont JP, Djouadi F, Bresson JL. Should the beneficial impact of bezafibrate on fatty acid oxidation disorders be questioned? J Inherit Metab Dis. 2015;38:371–2. [PubMed: 25310995]
• Boemer F, Deberg M, Schoos R, Caberg JH, Gaillez S, Dugauquier C, Delbecque K, François A, Maton P, Demonceau N, Senterre G, Ferdinandusse S, Debray FG. Diagnostic pitfall in antenatal manifestations of CPT II deficiency. Clin Genet. 2016;89:193–7. [PubMed: 25827434]
• Bonnefont JP, Bastin J, Laforêt P, Aubey F, Mogenet A, Romano S, Ricquier D, Gobin-Limballe S, Vassault A, Behin A, Eymard B, Bresson JL, Djouadi F. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin Pharmacol Ther. 2010;88:101–8. [PubMed: 20505667]
• Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360:838–40. [PubMed: 19228633]
• Bonnefont JP, Demaugre F, Prip-Buus C, Saudubray JM, Brivet M, Abadi N, Thuillier L. Carnitine palmitoyltransferase deficiencies. Mol Genet Metab. 1999;68:424–40. [PubMed: 10607472]
• Bonnefont JP, Djouadi F, Prip-Buus C, Gobin S, Munnich A, Bastin J. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med. 2004;25:495–520. [PubMed: 15363638]
• Bouchireb K, Teychene AM, Rigal O, de Lonlay P, Valayannopoulos V, Gaudelus J, Sellier N, Bonnefont JP, Brivet M, de Pontual L. Post-mortem MRI reveals CPT2 deficiency after sudden infant death. Eur J Pediatr. 2010;169:1561–3. [PubMed: 20661589]
• Chace DH. Mass spectrometry in the clinical laboratory. Chem Rev. 2001;101:445–77. [PubMed: 11712254]
• de Sain-van der Velden MG, Diekman EF, Jans JJ, van der Ham M, Prinsen BH, Visser G, Verhoeven-Duif NM. Differences between acylcarnitine profiles in plasma and bloodspots. Mol Genet Metab. 2013;110:116–21. [PubMed: 23639448]
• Deschauer M, Wieser T, Zierz S. Muscle carnitine palmitoyltransferase II deficiency: clinical and molecular genetic features and diagnostic aspects. Arch Neurol. 2005;62:37–41. [PubMed: 15642848]
• DiMauro S, DiMauro PM. Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science. 1973;182:929–31. [PubMed: 4745596]
• Durka-Kęsy M, Stępień A, Tomczykiewicz K, Fidziańska A, Niebrój-Dobosz I, Pastuszak Z. Myopathy in the course of carnitine palmitoyltransferase II deficiency. Neurol Neurochir Pol. 2012;46:600–2. [PubMed: 23319229]
• Elpeleg ON, Hammerman C, Saada A, Shaag A, Golzand E, Hochner-Celnikier D, Berger I, Nadjari M. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet. 2001;102:183–7. [PubMed: 11477613]
• Fanin M, Anichini A, Cassandrini D, Fiorillo C, Scapolan S, Minetti C, Cassanello M, Donati MA, Siciliano G, D'Amico A, Lilliu F, Bruno C, Angelini C. Allelic and phenotypic heterogeneity in 49 Italian patients with the muscle form of CPT-II deficiency. Clin Genet. 2012;82:232–9. [PubMed: 21913903]
• Fukushima T, Kaneoka H, Yasuno T, Sasaguri Y, Tokuyasu T, Tokoro K, Fukao T, Saito T. Three novel mutations in the carnitine-acylcarnitine translocase (CACT) gene in patients with CACT deficiency and in healthy individuals. J Hum Genet. 2013;58:788–93. [PubMed: 24088670]
• Gempel K, Kiechl S, Hofmann S, Lochmüller H, Kiechl-Kohlendorfer U, Willeit J, Sperl W, Rettinger A, Bieger I, Pongratz D, Gerbitz KD, Bauer MF. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis. 2002;25:17–27. [PubMed: 11999976]
• Hsiao YS, Jogl G, Esser V, Tong L. Crystal structure of rat carnitine palmitoyltransferase II (CPT-II). Biochem Biophys Res Commun. 2006;346:974–80. [PMC free article: PMC2937350] [PubMed: 16781677]
• Isackson PJ, Bennett MJ, Lichter-Konecki U, Willis M, Nyhan WL, Sutton VR, Tein I, Vladutiu GD. CPT2 gene mutations resulting in lethal neonatal or severe infantile carnitine palmitoyltransferase II deficiency. Mol Genet Metab. 2008;94:422–7. [PubMed: 18550408]
• Isackson PJ, Bennett MJ, Vladutiu GD. Identification of 16 new disease-causing mutations in the CPT2 gene resulting in carnitine palmitoyltransferase II deficiency. Mol Genet Metab. 2006;89:323–31. [PubMed: 16996287]
• Joshi PR, Young P, Deschauer M, Zierz S. Expanding mutation spectrum in CPT II gene: identification of four novel mutations. J Neurol. 2013;260:1412–4. [PubMed: 23475205]
• Joshi PR, Deschauer M, Zierz S. Carnitine palmitoyltransferase II (CPT II) deficiency: genotype-phenotype analysis of 50 patients. J Neurol Sci. 2014;338:107–11. [PubMed: 24398345]
• Kaneoka H, Uesugi N, Moriguchi A, Hirose S, Takayanagi M, Yamaguchi S, Shigematsu Y, Yasuno T, Sasatomi Y, Saito T. Carnitine palmitoyltransferase II deficiency due to a novel gene variant in a patient with rhabdomyolysis and ARF. Am J Kidney Dis. 2005;45:596–602. [PubMed: 15754283]
• Katsuya H, Misumi M, Ohtani Y, Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiology. 1988;68:945–8. [PubMed: 3256299]
• Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lücking CH. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord. 2001;11:757–9. [PubMed: 11595519]
• Motlagh L, Golbik R, Sippl W, Zierz S. Malony-CoA inhibits the S113L variant of carnitine-palmitoyltransferase II. Biochim Biophys Acta. 2016;1861:34–40. [PubMed: 26477380]
• Musumeci O, Aguennouz M, Comi GP, Rodolico C, Autunno M, Bordoni A, Baratta S, Taroni F, Vita G, Toscano A. Identification of the infant-type R631C mutation in patients with the benign muscular form of CPT2 deficiency. Neuromuscul Disord. 2007;17:960–3. [PubMed: 17651973]
• Norum KR. Palmityl-coa:carnitine palmityltransferase. Purification from calf-liver mitochondria and some properties of the enzyme. Biochim Biophys Acta. 1964;89:95–108. [PubMed: 14213015]
• Olpin SE, Afifi A, Clark S, Manning NJ, Bonham JR, Dalton A, Leonard JV, Land JM, Andresen BS, Morris AA, Muntoni F, Turnbull D, Pourfarzam M, Rahman S, Pollitt RJ. Mutation and biochemical analysis in carnitine palmitoyltransferase type II (CPT II) deficiency. J Inherit Metab Dis. 2003;26:543–57. [PubMed: 14605500]
• Ørngreen MC, Dunø M, Ejstrup R, Christensen E, Schwartz M, Sacchetti M, Vissing J. Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations. Ann Neurol. 2005;57:60–6. [PubMed: 15622536]
• Ørngreen MC, Madsen KL, Preisler N, Andersen G, Vissing J, Laforêt P. Bezafibrate in skeletal muscle fatty acid oxidation disorders: a randomized clinical trial. Neurology. 2014;82:607–13. [PMC free article: PMC3963421] [PubMed: 24453079]
• Pierce MR, Pridjian G, Morrison S, Pickoff AS. Fatal carnitine palmitoyltransferase II deficiency in a newborn: new phenotypic features. Clin Pediatr (Phila). 1999;38:13–20. [PubMed: 9924637]
• Preece MA, Green A. Pregnancy and inherited metabolic disorders: maternal and fetal complications. Ann Clin Biochem. 2002;39:444–55. [PubMed: 12227850]
• Rafay MF, Murphy EG, McGarry JD, Kaufmann P, DiMauro S, Tein I. Clinical and biochemical heterogeneity in an Italian family with CPT II deficiency due to Ser 113 Leu mutation. Can J Neurol Sci. 2005;32:316–20. [PubMed: 16225172]
• Rettinger A, Gempel K, Hofmann S, Gerbitz KD, Bauer MF. Tandem mass spectrometric assay for the determination of carnitine palmitoyltransferase II activity in muscle tissue. Anal Biochem. 2002;302:246–51. [PubMed: 11878804]
• Roe CR, Sweetman L, Roe DS, David F, Brunengraber H. Treatment of cardiomyopathy and rhabdomyolysis in long-chain fat oxidation disorders using an anaplerotic odd-chain triglyceride. J Clin Invest. 2002;110:259–69. [PMC free article: PMC151060] [PubMed: 12122118]
• Roe CR, Yang BZ, Brunengraber H, Roe DS, Wallace M, Garritson BK. Carnitine palmitoyltransferase II deficiency: successful anaplerotic diet therapy. Neurology. 2008;71:260–4. [PMC free article: PMC2676979] [PubMed: 18645163]
• Roe DS, Yang BZ, Vianey-Saban C, Struys E, Sweetman L, Roe CR. Differentiation of long-chain fatty acid oxidation disorders using alternative precursors and acylcarnitine profiling in fibroblasts. Mol Genet Metab. 2006;87:40–7. [PubMed: 16297647]
• Semba S, Yasujima H, Takano T, Yokozaki H. Autopsy case of the neonatal form of carnitine palmitoyltransferase-II deficiency triggered by a novel disease-causing mutation del1737C. Pathol Int. 2008;58:436–41. [PubMed: 18577113]
• Sharma R, Perszyk AA, Marangi D, Monteiro C, Raja S. Lethal neonatal carnitine palmitoyltransferase II deficiency: an unusual presentation of a rare disorder. Am J Perinatol. 2003;20:25–32. [PubMed: 12638078]
• Shekhawat PS, Matern D, Strauss AW. Fetal fatty acid oxidation disorders, their effect on maternal health and neonatal outcome: impact of expanded newborn screening on their diagnosis and management. Pediatr Res. 2005;57:78R–86R. [PMC free article: PMC3582391] [PubMed: 15817498]
• Shinohara M, Saitoh M, Takanashi J, Yamanouchi H, Kubota M, Goto T, Kikuchi M, Shiihara T, Yamanaka G, Mizuguchi M. Carnitine palmitoyl transferase II polymorphism is associated with multiple syndromes of acute encephalopathy with various infectious diseases. Brain Dev. 2011;33:512–7. [PubMed: 20934285]
• Sigauke E, Rakheja D, Kitson K, Bennett MJ. Carnitine palmitoyltransferase II deficiency: a clinical, biochemical, and molecular review. Lab Invest. 2003;83:1543–54. [PubMed: 14615409]
• Smeets RJ, Smeitink JA, Semmekrot BA, Scholte HR, Wanders RJ, van den Heuvel LP. A novel splice site mutation in neonatal carnitine palmitoyl transferase II deficiency. J Hum Genet. 2003;48:8–13. [PubMed: 12560872]
• Taggart RT, Smail D, Apolito C, Vladutiu GD. Novel mutations associated with carnitine palmitoyltransferase II deficiency. Hum Mutat. 1999;13:210–20. [PubMed: 10090476]
• Thuillier L, Rostane H, Droin V, Demaugre F, Brivet M, Kadhom N, Prip-Buus C, Gobin S, Saudubray JM, Bonnefont JP. Correlation between genotype, metabolic data, and clinical presentation in carnitine palmitoyltransferase 2 (CPT2) deficiency. Hum Mutat. 2003;21:493–501. [PubMed: 12673791]
• Vekemans BC, Bonnefont JP, Aupetit J, Royer G, Droin V, Attié-Bitach T, Saudubray JM, Thuillier L. Prenatal diagnosis of carnitine palmitoyltransferase 2 deficiency in chorionic villi: a novel approach. Prenat Diagn. 2003;23:884–7. [PubMed: 14634971]
• Vladutiu GD. Heterozygosity: an expanding role in proteomics. Mol Genet Metab. 2001;74:51–63. [PubMed: 11592803]
• Vladutiu GD, Bennett MJ, Fisher NM, Smail D, Boriack R, Leddy J, Pendergast DR. Phenotypic variability among first-degree relatives with carnitine palmitoyltransferase II deficiency. Muscle Nerve. 2002a;26:492–8. [PubMed: 12362414]
• Vladutiu GD, Bennett MJ, Smail D, Wong LJ, Taggart RT, Lindsley HB. A variable myopathy associated with heterozygosity for the R503C mutation in the carnitine palmitoyltransferase II gene. Mol Genet Metab. 2000a;70:134–41. [PubMed: 10873395]
• Vladutiu GD, Quackenbush EJ, Hainline BE, Albers S, Smail DS, Bennett MJ. Lethal neonatal and severe late infantile forms of carnitine palmitoyltransferase II deficiency associated with compound heterozygosity for different protein truncation mutations. J Pediatr. 2002b;141:734–6. [PubMed: 12410208]
• Vladutiu GD, Quackenbush E, Hainline BE, Smail D, Bennett MJ. Variable phenotypes associated with a protein truncation mutation in carnitine palmitoyltransferase II deficiency. Am J Hum Genet. 2000b;67:1552.
• Wataya K, Akanuma J, Cavadini P, Aoki Y, Kure S, Invernizzi F, Yoshida I, Kira J, Taroni F, Matsubara Y, Narisawa K. Two CPT2 mutations in three Japanese patients with carnitine palmitoyltransferase II deficiency: functional analysis and association with polymorphic haplotypes and two clinical phenotypes. Hum Mutat. 1998;11:377–86. [PubMed: 9600456]
• Wieser T, Deschauer M, Olek K, Hermann T, Zierz S. Carnitine palmitoyltransferase II deficiency: molecular and biochemical analysis of 32 patients. Neurology. 2003;60:1351–3. [PubMed: 12707442]
• Wieser T, Kraft B, Kress HG. No carnitine palmitoyltransferase deficiency in skeletal muscle in 18 malignant hyperthermia susceptible individuals. Neuromuscul Disord. 2008;18:471–4. [PubMed: 18430572]
• Yahyaoui R, Espinosa MG, Gómez C, Dayaldasani A, Rueda I, Roldán A, Ugarte M, Lastra G, Pérez V. Neonatal carnitine palmitoyltransferase II deficiency associated with Dandy-Walker syndrome and sudden death. Mol Genet Metab. 2011;104:414–6. [PubMed: 21641254]
• Yamamoto T, Tanaka H, Emoto Y, Umehara T, Fukahori Y, Kuriu Y, Matoba R, Ikematsu K. Carnitine palmitoyltransferase 2 gene polymorphism is a genetic risk factor for sudden unexpected death in infancy. Brain Dev. 2014;36:479–83. [PubMed: 23969168]
• Yasuno T, Kaneoka H, Tokuyasu T, Aoki J, Yoshida S, Takayanagi M, Ohtake A, Kanazawa M, Ogawa A, Tojo K, Saito T. Mutations of carnitine palmitoyltransferase II (CPT II) in Japanese patients with CPT II deficiency. Clin Genet. 2008;73:496–501. [PubMed: 18363739]
• Yoshino M, Tokunaga Y, Watanabe Y, Yoshida I, Sakaguchi M, Hata I, Shigematsu Y, Kimura M, Yagamuchi S. Effect of supllementation of L-carnitine at a small dose on acylcarnitine profiles in serum and urine and the renal handling of acylcarntintines in a patient with multiple acylcoenzyme A dehydrogenation defect. J. Chromatogr B Analyt Technol Biomed Life Sci. 2003;792:73–82. [PubMed: 12828999]
• Zierz S, Engel AG. Regulatory properties of a mutant carnitine palmitoyltransferase in human skeletal muscle. Eur J Biochem. 1985;149:207–14. [PubMed: 3996401]